Prospective Biomarker Analysis of Patients With Metastatic Castration-resistant Prostate Cancer (mCRPC) Undergoing Sequential Treatment With Docetaxel and Enzalutamide
Latest Information Update: 17 Apr 2024
At a glance
- Drugs Docetaxel (Primary) ; Enzalutamide (Primary)
- Indications Prostate cancer
- Focus Biomarker; Pharmacogenomic; Therapeutic Use
- 11 Apr 2024 Planned End Date changed from 1 Jul 2023 to 1 Apr 2025.
- 14 Sep 2022 Planned End Date changed from 1 Dec 2022 to 1 Jul 2023.
- 14 Sep 2022 Planned primary completion date changed from 1 Jun 2022 to 1 Mar 2023.